ExpreS2ion Biotech Holding AB (FRA:5JD0) Scaled Net Operating Assets: 0.08 (As of Mar. 2026)


FRA:5JD0 ExpreS2ion Biotech Holding AB FRA:5JD0
43 GF Score
Price €0.04
GF Value €0.09
! 5 Warning Signs
View Full Analysis

What is ExpreS2ion Biotech Holding AB Scaled Net Operating Assets?

ExpreS2ion Biotech Holding AB FRA:5JD0 -7.41% 43 Scaled Net Operating Assets is 0.08 as of Mar. 2026. GuruFocus rates FRA:5JD0 with a GF Score™ of 43/100 and a GF Value™ of €0.09. The stock has 5 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

ExpreS2ion Biotech Holding AB's operating assets for the quarter that ended in Mar. 2026 was €2.65 Mil. ExpreS2ion Biotech Holding AB's operating liabilities for the quarter that ended in Mar. 2026 was €2.18 Mil. ExpreS2ion Biotech Holding AB's Total Assets for the quarter that ended in Dec. 2025 was €5.98 Mil. Therefore, ExpreS2ion Biotech Holding AB's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.08.


ExpreS2ion Biotech Holding AB Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for ExpreS2ion Biotech Holding AB's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ExpreS2ion Biotech Holding AB Scaled Net Operating Assets Chart

ExpreS2ion Biotech Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 -0.04 0.07 -0.19 -0.11

ExpreS2ion Biotech Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.07 -0.04 -0.17 0.08

FRA:5JD0 vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ExpreS2ion Biotech Holding AB Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where ExpreS2ion Biotech Holding AB's Scaled Net Operating Assets falls into.


FRA:5JD0
43GF Score
ExpreS2ion Biotech Holding AB FRA:5JD0
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ExpreS2ion Biotech Holding AB Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

ExpreS2ion Biotech Holding AB's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(1.613-2.58)/9.121
=-0.11

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5.983 - 4.37
=1.613

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.704 - 0.078 - 0.046
=2.58

ExpreS2ion Biotech Holding AB's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(2.651-2.179)/5.983
=0.08

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=4.679 - 2.028
=2.651

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.227 - 0 - 0.048
=2.179

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.08 mean?
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a Scaled Net Operating Assets of 0.08 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on ExpreS2ion Biotech Holding AB and its competitors.
Is ExpreS2ion Biotech Holding AB's Scaled Net Operating Assets too high?
ExpreS2ion Biotech Holding AB's current Scaled Net Operating Assets is 0.08. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's Scaled Net Operating Assets compare to VRTX and REGN?
ExpreS2ion Biotech Holding AB's Scaled Net Operating Assets of 0.08 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on ExpreS2ion Biotech Holding AB and its competitors. ExpreS2ion Biotech Holding AB's current Scaled Net Operating Assets is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a current Scaled Net Operating Assets of 0.08. The stock's GF Value™ is €0.09, compared to a current price of €0.04 — trading 61.1% below its estimated fair value. The current Scaled Net Operating Assets is 0.08. ExpreS2ion Biotech Holding AB's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (FRA:5JD0), the current Scaled Net Operating Assets is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ExpreS2ion Biotech Holding AB (FRA:5JD0) Overvalued in 2026?

Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued. The current stock price of €0.04 is trading 61.1% below its estimated GF Value™ of €0.09.

Key valuation signals for FRA:5JD0:

  • Scaled Net Operating Assets: 0.08
  • GF Value™: €0.09 vs. price of €0.04 (61.1% below fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the FRA:5JD0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ExpreS2ion Biotech Holding AB Business Description

Other Exchanges EXPRS2:Sweden
Address c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, 252 25
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score

Get the complete analysis for FRA:5JD0

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.04
Price
€0.09
GF Value